


Innovative
Medicine
for everyone
everywhere



ADOCIA

innovative medicine
for everyone, everywhere



Adocia at a glance

1

Mission: to develop innovative peptide formulations for diabetes and obesity treatment

2

Business model: Licensing-out our products and technologies after proof of concept

3

2 partners: Tonghua Dongbao (BC Lispro, licensed for Asia) & Sanofi (exclusive option on M1Pram)


4

Assets: 1 ready for submission in China, 2 clinical stage specialty products (Ph. 1 to 2) and 4 proprietary technology platforms

5

Leading a team of **80 experts, including 35 PhDs/MDs/PharmDs**, based in Lyon, France

Diabetes and Obesity



ADOCIA

115 Avenue Lacassagne, 69003 Lyon, France

+33(0)4 72 610 610

contact@adocia.com

www.adocia.com

Pipeline

Platform	Program	Targeted Indications	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory	Partner
BioChaperone®	Lispro <i>Ultra-Rapid Insulin</i>	DIABETES						 通化東寶 Tong Hua Dong Bao Group
	GLP-1 / Amylin <i>Combine obesity treatments</i>	OBESITY DIABETES						
AdoXLong™	GLP-1 <i>Once-monthly GLP-1</i>	OBESITY DIABETES						
AdOral®	GLP-1 <i>Oral Delivery of GLP-1</i>	OBESITY DIABETES						
AdoShell®	Cell Therapy <i>Peptide-secreting cells delivery</i>	DIABETES						
	M1Pram <i>Insulin-pramlintide combination</i>	OBESITY DIABETES						sanofi

4 technological platforms

 BioChaperone® <i>Formulation and co-formulation of peptides</i> Unlock peptide combinations ✓ Stabilizing or combining peptides ✓ Improving efficacy by accelerating insulin action	 AdoXLong™ <i>Long-acting peptides</i> Reduce frequency of injections and increase manufacturing capacity ✓ Permitting a once-a-month injection	 AdOral® <i>Oral delivery of peptides</i> Avoid injections and sterile manufacturing ✓ Improving oral bioavailability of peptide	 AdoShell® <i>Peptide-secreting cells delivery</i> Develop a potential functional cure for T1D without immunosuppressors ✓ Protecting islets against immune system ✓ Ensuring islets retrievability
---	---	---	--

